ScienceJapan1 sourcesNeutral

China-developed triple incretin enters global diabetes race

A next-generation triple incretin therapy jointly developed by Novo Nordisk A/S and China’s United Biotechnology outperformed semaglutide in a phase II trial, signaling intensifying competition in the GLP-1 obesity and diabetes market.

tamra sami

via Bioworld

March 26, 2026 | 4:00 PM UTCUpdated 2h ago

Share Read original

Read the full article at Bioworld →

China-developed triple incretin enters global diabetes race

Source Verification

Corroboration Score: 1

This story was independently reported by 1 sources. Click any source to read the original article.

Bioworld

NewsDataJP

Comments

0 comments

Be respectful and constructive.

Loading comments...

China-developed triple incretin enters global diabetes race

Source Verification

Comments

Your brain reacts to nature in ways scientists can now measure

Labyrinth Anime Movie Gets New Trailer & Poster

Related Articles

Wave stock shaken, analysts stirred by 007’s obesity phase I

Idel raises $10.4M for intracellular pan-cancer drug delivery tech

Korea roundup: Alteogen, Celltrion lead biotech deals